Phoenix Solutions AS completes its Series C financing

The Board of Directors of Phoenix Solutions is pleased to announce that the company has completed a series C financing led by current shareholder and an expanded group of healthcare angel investors. CEO Per Sontum; "We are very pleased to announce this third round of financing which will fully fund our first clinical phase I/IIa program for treatment of hepatic metastases from colon and pancreatic cancer, anticipated to start H1 2019. Furthermore, this placement will enable us to expand our pre-clinical program, exploring ACT® in other medicinal segments including biologics for cancer, CNS and infectious diseases. Finally, it will allow us to start preparations for a Phase I/IIa with ACT® for treatment of locally advanced pancreatic cancer”.